{"doi":"10.1037/neu0000981","title":"Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.","abstract":"OBJECTIVE: Objectively defined subtle cognitive decline (Obj-SCD) is an emerging classification that may identify individuals at risk for future decline and progression to Alzheimer's disease prior to a diagnosis of mild cognitive impairment (MCI). Growth-associated protein 43 (GAP-43), a cerebrospinal fluid (CSF) marker of synaptic dysfunction, has been shown to relate to an increased risk of converting to dementia, although it is unclear whether GAP-43 alterations may be detected in pre-MCI stages. Therefore, in the present study, we examined CSF GAP-43 levels among individuals with Obj-SCD cross-sectionally and also examined whether baseline GAP-43 predicts future functional decline. METHOD: Six hundred forty-four participants from the Alzheimer's Disease Neuroimaging Initiative were divided into six groups based on (a) cognitive status (cognitively unimpaired [CU], Obj-SCD, or MCI) and (b) Aβ status (+ or -). RESULTS: The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups. Higher GAP-43 levels were associated with faster decline across the entire sample. When moderation by group was examined, higher GAP-43 at baseline predicted faster functional decline for the Obj-SCD+ and MCI+ groups, compared to the CU- group. CONCLUSIONS: Results extend prior work investigating biomarker associations in Obj-SCD to GAP-43 and show that high baseline CSF GAP-43 is associated with a faster rate of functional decline in Aβ+ individuals who are classified as Obj-SCD or MCI. Importantly, our findings further demonstrate that CSF GAP-43 is associated with early and subtle cognitive changes detectable before the onset of MCI. (PsycInfo Database Record (c) 2025 APA, all rights reserved).","journal":"Neuropsychology","year":2025,"id":532063,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9635,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":900261,"name":"Lauren C. Edwards","orcid":null,"position":1,"is_corresponding":false},{"id":316753,"name":"Kelsey R. Thomas","orcid":"0000-0003-4277-8876","position":2,"is_corresponding":false},{"id":316752,"name":"Alexandra J. Weigand","orcid":"0000-0002-7931-1383","position":3,"is_corresponding":false},{"id":906426,"name":"Maria Bordyug","orcid":null,"position":4,"is_corresponding":false},{"id":905843,"name":"Einat K. Brenner","orcid":"0000-0002-0172-8277","position":5,"is_corresponding":false},{"id":1315604,"name":"Uriel Urias","orcid":null,"position":6,"is_corresponding":false},{"id":316754,"name":"Katherine J. Bangen","orcid":"0000-0002-1363-3179","position":7,"is_corresponding":false},{"id":1404216,"name":"Amanda Gonzalez","orcid":"0000-0001-9231-0353","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:51:18.928280Z","pmid":"40063372","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}